ENXTPA:BIM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases.


Snowflake Analysis

Flawless balance sheet with acceptable track record.


Similar Companies

Share Price & News

How has bioMérieux's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.5%

BIM

-11.5%

FR Medical Equipment

9.2%

FR Market


1 Year Return

51.5%

BIM

42.8%

FR Medical Equipment

-2.3%

FR Market

Return vs Industry: BIM exceeded the French Medical Equipment industry which returned 42.8% over the past year.

Return vs Market: BIM exceeded the French Market which returned -2.4% over the past year.


Shareholder returns

BIMIndustryMarket
7 Day-12.5%-11.5%9.2%
30 Day-4.6%-3.5%14.1%
90 Day38.2%35.8%5.8%
1 Year51.5%51.5%42.8%42.8%-0.6%-2.3%
3 Year73.8%72.2%43.9%42.2%11.4%2.5%
5 Year247.2%239.3%144.5%138.9%31.9%15.0%

Price Volatility Vs. Market

How volatile is bioMérieux's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is bioMérieux undervalued compared to its fair value and its price relative to the market?

48.96x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BIM (€112.9) is trading above our estimate of fair value (€69.6)

Significantly Below Fair Value: BIM is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BIM is poor value based on its PE Ratio (49x) compared to the Medical Equipment industry average (44.3x).

PE vs Market: BIM is poor value based on its PE Ratio (49x) compared to the French market (15.4x).


Price to Earnings Growth Ratio

PEG Ratio: BIM is poor value based on its PEG Ratio (4.3x)


Price to Book Ratio

PB vs Industry: BIM is overvalued based on its PB Ratio (6.1x) compared to the FR Medical Equipment industry average (2.7x).


Next Steps

Future Growth

How is bioMérieux forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

11.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIM's forecast earnings growth (11.5% per year) is above the savings rate (0.6%).

Earnings vs Market: BIM's earnings (11.5% per year) are forecast to grow slower than the French market (13.7% per year).

High Growth Earnings: BIM's earnings are forecast to grow, but not significantly.

Revenue vs Market: BIM's revenue (7.5% per year) is forecast to grow faster than the French market (4.1% per year).

High Growth Revenue: BIM's revenue (7.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BIM's Return on Equity is forecast to be low in 3 years time (13.2%).


Next Steps

Past Performance

How has bioMérieux performed over the past 5 years?

18.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIM has high quality earnings.

Growing Profit Margin: BIM's current net profit margins (10.2%) are lower than last year (10.6%).


Past Earnings Growth Analysis

Earnings Trend: BIM's earnings have grown by 18.1% per year over the past 5 years.

Accelerating Growth: BIM's earnings growth over the past year (6.4%) is below its 5-year average (18.1% per year).

Earnings vs Industry: BIM earnings growth over the past year (6.4%) exceeded the Medical Equipment industry -2%.


Return on Equity

High ROE: BIM's Return on Equity (12%) is considered low.


Next Steps

Financial Health

How is bioMérieux's financial position?


Financial Position Analysis

Short Term Liabilities: BIM's short term assets (€1.4B) exceed its short term liabilities (€1.2B).

Long Term Liabilities: BIM's short term assets (€1.4B) exceed its long term liabilities (€357.2M).


Debt to Equity History and Analysis

Debt Level: BIM's debt to equity ratio (20.5%) is considered satisfactory.

Reducing Debt: BIM's debt to equity ratio has reduced from 26.4% to 20.5% over the past 5 years.

Debt Coverage: BIM's debt is well covered by operating cash flow (88.3%).

Interest Coverage: BIM's interest payments on its debt are well covered by EBIT (18.6x coverage).


Balance Sheet


Next Steps

Dividend

What is bioMérieux's current dividend yield, its reliability and sustainability?

0.17%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: BIM's dividend (0.17%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.64%).

High Dividend: BIM's dividend (0.17%) is low compared to the top 25% of dividend payers in the French market (4.77%).


Stability and Growth of Payments

Stable Dividend: BIM is not paying a notable dividend for the French market, therefore no need to check if payments are stable.

Growing Dividend: BIM is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: BIM is not paying a notable dividend for the French market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIM's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Alexandre Mérieux (45yo)

2.5yrs

Tenure

€1,310,165

Compensation

Mr. Alexandre Mérieux serves as the Chairman and Chief Executive Officer of bioMérieux, Inc. Mr. Mérieux serves as the President and Chairman of the Management Board of Merieux Développement SAS. He joined ...


CEO Compensation Analysis

Compensation vs Market: Alexandre's total compensation ($USD1.48M) is below average for companies of similar size in the French market ($USD3.89M).

Compensation vs Earnings: Alexandre's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Alexandre Mérieux
Chairman & CEO2.5yrs€1.31m0.000050% 6.7k
Frédéric Besème
Employee Director & Head of CSR2.08yrs€13.12k0.0025% 332.6k
Guillaume Bouhours
Executive VP of Purchasing and Information Systems & CFO2.25yrsno datano data
Pierre Boulud
Executive VP of Clinical Operations & COOno datano datano data
Sylvain Morgeau
Investor Relationsno datano datano data
Esther Wick
Executive Vice President of Legalno datano datano data
Valérie Leyldé
Executive VP of Human Resources & Communications1.42yrsno datano data
François Lacoste
Executive Vice President of R&D2.25yrsno datano data
Mark Miller
Executive VP & Chief Medical Officer7.67yrsno datano data
Pierre Charbonnier
Executive Vice President of Global Quality2.25yrsno datano data

2.3yrs

Average Tenure

46.5yo

Average Age

Experienced Management: BIM's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Alexandre Mérieux
Chairman & CEO2.5yrs€1.31m0.000050% 6.7k
Frédéric Besème
Employee Director & Head of CSR2.08yrs€13.12k0.0025% 332.6k
Alain Merieux
Founding Chairman2.83yrsno datano data
Jean-Luc Bélingard
Non-Independent Director13.75yrs€41.00k0.00013% 17.4k
Philippe Archinard
Non-Independent Director10yrs€55.00k0.000030% 4.0k
Harold Y. Boël
Independent Director8.08yrs€55.00k0.00013% 17.4k
Agnès Lemarchand
Independent Director6.08yrs€46.00k0.00013% 17.4k
Marie-Hélène Habert-Dassault
Independent Director8.08yrs€36.00k0.000050% 6.7k
Fanny Letier
Independent Director3.08yrs€36.00k0.000030% 4.0k
Marie-Paule Kieny
Independent Director2.83yrs€30.00k0.00015% 20.0k

4.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: BIM's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

bioMérieux S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: bioMérieux S.A.
  • Ticker: BIM
  • Exchange: ENXTPA
  • Founded: 1963
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €13.356b
  • Shares outstanding: 118.30m
  • Website: https://www.biomerieux.com

Number of Employees


Location

  • bioMérieux S.A.
  • 376 Chemin De l’Orme
  • Marcy l'Etoile
  • Rhône-Alpes
  • 69280
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMXM.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2004
BIMENXTPA (Euronext Paris)YesOrdinary SharesFREURJul 2004
0RUGLSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2004
EYWNDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2004
BIMPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJul 2004

Biography

bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involves culturing biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as measures the specific biomarkers of various pathologies, such as metabolic, hormonal, infectious, etc. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test based on biomarkers, as well as services for clinical and industrial laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is based in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/06 23:22
End of Day Share Price2020/06/05 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.